Chief Executive Officer
Sara has leadership experience both financially and operationally with a focus upon developing and commercialising life science products. She was the CEO of LungLife AI a diagnostic company for early stage lung cancer. Prior to that she was with Bruin Biometrics, a LA-based medical device company as EVP Business Operations and previously CFO. In her role at Exosome Diagnostics, a venture-backed personalised medicine company the focus was upon the development of non-invasive liquid biopsy diagnostics in cancer and the company was successfully sold to Bio-Techne Corporation in 2018. She was previously CFO at AusAm Biotechnologies developing diagnostics in kidney disease. Prior to working in the US, she worked for British Telecom in London in business development and strategy.
Sara received her B.A. from Lancaster University and she is qualified as a Chartered Accountant with the Institute of Chartered Accountants in England and Wales. She has also qualified with Chartered Institute of Marketing.
Sara was appointed a director of the Company on 19 August 2020.
Non-Executive Chairman
Member of the remuneration committee
Julian is Executive Chair of EKF Diagnostics Holdings plc. During his tenure at EKF, he has successfully
completed multiple fundraisings and the acquisition and subsequent integration of eight businesses in seven
countries, building revenue from zero to over £40,000,000. Prior to joining EKF, Julian was group chief
executive officer of BBI Holdings plc, where he undertook a management buyout in 2000, its AIM flotation in
2004 and was responsible for selling the business to Alere, Inc. (now part of Abbott Laboratories) in 2008 for c.
£85,000,000.
In 2016, Julian was awarded an MBE for services to the life sciences industry. Julian was appointed a Non-Executive Director of the Company on 22 April 2020.
Non-Executive Director
Member of the remuneration committee and CEO of Renalytix AI plc
James has experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. His skills include equity and debt capital formation, strategic development and partnerships, executive team structuring, regulatory issues and marketing. The Renalytix IPO was completed in November 2018, raising over £22,000,000 for the company. Following successful progress in validatory development, regulatory discussions, reimbursement, pricing and insurance coverage determinations, a follow-on fundraise was arranged in July 2019 at over double the IPO price, enabling expansion of the team and acceleration of key workstreams. In July 2020, Renalytix successfully dual-listed on Nasdaq with a market capitalisation of £65.12 million after raising a further $85 million (approximately £68 million).
Prior to his role at Renalytix, James was Chief Executive Officer of Exosome Diagnostics, a venture backed personalised medicine company developing non-invasive liquid biopsy diagnostics in cancer. Exosome Diagnostics was acquired by Bio-Techne Corporation (NASDAQ: TECH) in 2018.
James received his B.A. from Boston University and an M.B.A. from Columbia Business School. James is currently Chairman of BalletNext, a performing arts company in New York City.
James was appointed a director of the Company on 22 April 2020.
Non-Executive Director
Member of the remuneration committee and representative of Mount Sinai on the Board
Dr. Lium is President of Mount Sinai Innovation Partners (MSIP) and Executive Vice President and Chief Commercial Innovation Officer, Mount Sinai Health System. He is also Non-Executive Director of Renalytix. Dr Lium represents Mount Sinai on several private company boards and previously served as a member of the investment review committee for the Accelerate NY Seed Fund. Dr Lium also serves as chairman of the board of managers of Kantaro.
Prior to joining Mount Sinai, Dr. Lium served as the Assistant Vice Chancellor of Innovation, Technology & Alliances at the University of California, San Francisco (UCSF), and the UCSF Principal Investigator for the Bay area National Science Foundation I-Corps node and Assistant Vice Chancellor of. Dr. Lium served as President of LabVelocity Inc. prior to its acquisition in 2004. He pursued post-doctoral research at UCSF in the laboratory of J. Michael Bishop, MD, and earned a PhD with honours from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein. Dr. Lium holds a BS in Biology from Gonzaga University.
Dr. Lium was appointed a director of the Company on the 19 August 2020.
Senior Independent Non-Executive Director
Chair of the audit committee and nomination committee
Sir Ian Carruthers holds a number of chair and non-executive board and advisory roles in the public and private sectors. He was previously Chief Executive of NHS South of England, comprising three health bodies: South West, South Central and South East and his career in the National Health Services spans over 40 years. He was awarded the Order of the British Empire for services to health in 1997 and a Knighthood in 2003 for services to the NHS and in 2006 he took over as Interim Chief Executive of NHS England, amongst the largest organisations in the world with over 1.3 million employees and a budget in excess of £100 billion. He has been the lead author on several papers on reviewing and improving the NHS and is seen as an international expert on healthcare systems and service delivery.
He is currently Chancellor of the University of the West of England, and was formerly Chair of Healthcare UK, Chair of the Innovation Health and Wealth Implementation Board, Co-Chair of the Prime Minister’s Challenge on Dementia and Non-Executive Director of Bioquell plc.
Sir Ian Carruthers was appointed as a director of the Company on 19 August 2020.
Independent Non-Executive Director
Member of the Audit Committee
Dr Gallon is Professor of Medicine and Surgery, Director, Abdominal Organ Transplant Program at the University of Illinois, Chicago. He is an alumnus of the University of Padua Medical School, Italy and Harvard Medical School.
An expert in nephrology and hypertension as well as organ transplantation, Dr. Gallon’s primary research interests include:
With 20 years’ experience in the life sciences industry, focusing largely on nephrology and organ transplantation, Dr. Gallon is excellently placed to provide insight and guidance in the development of Verici’s two lead products, Clarava™ and Tutivia™. He was a collaborator and co-author with Verici’s previous SAB Chair, Dr. Barbara Murphy, in the GoCar study which was foundational in the development of Verici’s products. He has also been a member of the Editorial Board at the journal Nephron since 2019.
Company Secretary
David is a chartered accountant and member of the Institute of Chartered Accountants of England and Wales with over 28 years experience of senior finance roles. He qualified with Stoy Hayward (now BDO LLP) and from 1998 to 2009 was an audit partner in their London office before becoming an audit partner with Crowe Clark Whitehill (now Crowe U.K. LLP) from 2010 to 2012. Since then he has held senior finance roles with Strategic Minerals Plc, Hakkasan Limited and CT Group International Ltd. He is currently also the CFO and board member of LungLife AI, Inc.
